黄热病疫苗接种后的效力和免疫持续时间：关于每 10 年加强免疫的必要性的系统评价。
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.
机构信息
Instituto de Medicina Tropical Alexander von Humbolt, Lima, Peru.
出版信息
Am J Trop Med Hyg. 2013 Sep;89(3):434-44. doi: 10.4269/ajtmh.13-0264.
Abstract
Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.
摘要
摘要。现行法规规定每 10 年接种一次黄热病（YF）加强针。我们对黄热病疫苗在疾病流行地区居民和旅行者中的保护效力和免疫持续时间进行了系统评价，以评估在这两种情况下以及在某些特定人群（感染人类免疫缺陷病毒者、婴儿、儿童、孕妇和严重营养不良者）中是否需要加强针。共纳入 36 项研究和 22 份报告。我们确定了 12 项关于免疫原性的研究、8 项关于免疫持久性的研究、8 项关于婴儿和儿童疫苗反应的研究、7 项关于感染人类免疫缺陷病毒者的研究、2 项关于孕妇的研究和 1 项关于严重营养不良儿童的研究。基于现有数据，YF 疫苗单剂具有高度免疫原性，并能对 YF 提供持续终身的保护作用。因此，不需要接种 YF 疫苗加强针。详细说明了某些特定人群的特殊考虑因素。
相似文献
1
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.黄热病疫苗接种后的效力和免疫持续时间：关于每 10 年加强免疫的必要性的系统评价。
Am J Trop Med Hyg. 2013 Sep;89(3):434-44. doi: 10.4269/ajtmh.13-0264.
2
Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression.婴幼儿初次接种黄热病疫苗的体液免疫原性：一项系统评价、荟萃分析和荟萃回归分析
J Travel Med. 2024 Apr 6;31(3). doi: 10.1093/jtm/taae039.
3
Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.黄热病疫苗 17D 或 17DD 相关严重不良事件的主动和被动监测：系统评价。
Vaccine. 2011 Jun 20;29(28):4544-55. doi: 10.1016/j.vaccine.2011.04.055. Epub 2011 May 5.
4
Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis.黄热病疫苗接种后的长期免疫：一项系统评价和荟萃分析。
Lancet Glob Health. 2024 Mar;12(3):e445-e456. doi: 10.1016/S2214-109X(23)00556-9. Epub 2024 Jan 22.
5
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.单次接种 17DD 黄热病减毒活疫苗后短暂的免疫持久性表明，为保证儿童的保护性免疫，可能需要加强免疫接种。
Front Immunol. 2019 Sep 26;10:2192. doi: 10.3389/fimmu.2019.02192. eCollection 2019.
6
Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.黄热病疫苗在人类免疫缺陷病毒感染者中的免疫原性和保护持续时间：系统评价。
Clin Microbiol Infect. 2021 Jul;27(7):958-967. doi: 10.1016/j.cmi.2021.03.004. Epub 2021 Apr 1.
7
Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.免疫介导性炎症疾病、实体器官移植或骨髓移植患者接受免疫抑制治疗时进行活疫苗接种的安全性——对随机试验、观察性研究和病例报告的系统评价
Vaccine. 2017 Mar 1;35(9):1216-1226. doi: 10.1016/j.vaccine.2017.01.048. Epub 2017 Feb 3.
8
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力：系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
9
Vaccines for preventing typhoid fever.预防伤寒热的疫苗。
Cochrane Database Syst Rev. 2018 May 31;5(5):CD001261. doi: 10.1002/14651858.CD001261.pub4.
10
Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity.在非流行地区的一组成人和儿童中，单剂量17DD黄热病疫苗的免疫原性及其与登革热和寨卡病毒血清阳性的关联。
PLoS Negl Trop Dis. 2025 Apr 9;19(4):e0012993. doi: 10.1371/journal.pntd.0012993. eCollection 2025 Apr.
引用本文的文献
1
Preexisting yellow fever virus and West Nile virus immunity and pregnancy outcomes in a Nigerian cohort with endemic orthoflavivirus exposure.在尼日利亚一个地方性黄病毒暴露队列中，既往黄热病病毒和西尼罗河病毒免疫情况与妊娠结局
Emerg Microbes Infect. 2025 Dec;14(1):2544720. doi: 10.1080/22221751.2025.2544720. Epub 2025 Aug 21.
2
A Single Dose of Yellow Fever Vaccine Provides Long-Term Immunity in Japanese Travelers.一剂黄热病疫苗可为日本旅行者提供长期免疫力。
Vaccines (Basel). 2025 Jun 24;13(7):675. doi: 10.3390/vaccines13070675.
3
Profile of the B cell receptor repertoire and antibody responses upon 17DD-YF vaccine boosting.17DD-YF疫苗加强免疫后的B细胞受体库及抗体反应概况
bioRxiv. 2025 Jul 1:2025.06.24.660700. doi: 10.1101/2025.06.24.660700.
4
Yellow Fever Virus Interactomes Reveal Common and Divergent Strategies of Replication and Evolution for Mosquito-borne Flaviviruses.黄热病病毒相互作用组揭示蚊媒黄病毒复制与进化的共同和不同策略。
bioRxiv. 2025 Jul 1:2025.06.14.659623. doi: 10.1101/2025.06.14.659623.
5
Evidence map of strategies for preventing and controlling infestation and related viral infections.预防和控制感染及相关病毒感染策略的证据图谱。
Rev Panam Salud Publica. 2025 Jun 23;49:e63. doi: 10.26633/RPSP.2025.63. eCollection 2025.
6
Pathogenicity and virulence of Powassan virus.波瓦桑病毒的致病性和毒力
Virulence. 2025 Dec;16(1):2523887. doi: 10.1080/21505594.2025.2523887. Epub 2025 Jun 26.
7
From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.从抗体到免疫：评估黄病毒保护和交叉反应的相关因素。
Vaccines (Basel). 2025 Apr 24;13(5):449. doi: 10.3390/vaccines13050449.
8
A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses.一种针对黄热病和寨卡病毒的二价自我扩增RNA疫苗。
Front Immunol. 2025 Apr 29;16:1569454. doi: 10.3389/fimmu.2025.1569454. eCollection 2025.
9
Interferon-induced activation of dendritic cells and monocytes by yellow fever vaccination correlates with early antibody responses.黄热病疫苗接种诱导的树突状细胞和单核细胞激活与早期抗体反应相关。
Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2422236122. doi: 10.1073/pnas.2422236122. Epub 2025 May 7.
10
Yellow Fever in Non-Human Primates: A Veterinary Guide from a One Health Perspective.非人灵长类动物中的黄热病：从“同一个健康”视角出发的兽医指南
Vet Sci. 2025 Apr 6;12(4):339. doi: 10.3390/vetsci12040339.
本文引用的文献
1
Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.在马里的一次预防免疫活动后，115 名 HIV 感染者中的黄热病疫苗的免疫原性和安全性。
Trans R Soc Trop Med Hyg. 2012 Jul;106(7):437-44. doi: 10.1016/j.trstmh.2012.04.002. Epub 2012 May 22.
2
Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients.血浆 HIV-RNA 是 364 例 HIV 感染患者队列中黄热病免疫后长期抗体持续存在的关键决定因素。
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):360-7. doi: 10.1097/QAI.0b013e318249de59.
3
Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.描述在巴西累西腓进行的 17DD 黄热病疫苗前瞻性队列研究。
Am J Trop Med Hyg. 2011 Oct;85(4):739-47. doi: 10.4269/ajtmh.2011.10-0496.
4
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.修订后的全球黄热病风险地图和接种建议，2010 年：世界卫生组织非正式黄热病地理风险工作组的共识。
Lancet Infect Dis. 2011 Aug;11(8):622-32. doi: 10.1016/S1473-3099(11)70147-5.
5
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.免疫保护相关的黄热病通过在仓鼠模型中的被动免疫和攻毒实验确定。
Vaccine. 2011 Aug 11;29(35):6008-16. doi: 10.1016/j.vaccine.2011.06.034. Epub 2011 Jun 28.
6
Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.黄热病疫苗 17D 或 17DD 相关严重不良事件的主动和被动监测：系统评价。
Vaccine. 2011 Jun 20;29(28):4544-55. doi: 10.1016/j.vaccine.2011.04.055. Epub 2011 May 5.
7
[Long term persistence of yellow fever neutralising antibodies in elderly persons].[老年人中黄热病中和抗体的长期持续存在]
Bull Soc Pathol Exot. 2011 Oct;104(4):260-5. doi: 10.1007/s13149-011-0135-7. Epub 2011 Feb 18.
8
Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk.病例报告：婴儿通过母乳感染黄热病毒疫苗株。
CMAJ. 2011 Mar 8;183(4):E243-5. doi: 10.1503/cmaj.100619. Epub 2011 Feb 7.
9
Meeting of the Global Advisory Committee on Vaccine Safety, December 2010.全球疫苗安全咨询委员会会议，2010年12月
Wkly Epidemiol Rec. 2011 Jan 28;86(5):38-43.
10
Yellow fever vaccination coverage among children in Brazilian capitals.巴西首都儿童的黄热病疫苗接种覆盖率。
Vaccine. 2010 Sep 7;28(39):6478-82. doi: 10.1016/j.vaccine.2010.07.035. Epub 2010 Jul 30.
Zotero 插件